Immunology Drugmaker Electra Falls 12% After Upsized US IPO
The clinical-stage developer drops in its trading debut after raising $350 million in an upsized initial public offering.
This story has stopped developing; this page is its permanent record. More from that day
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Electra Therapeutics Inc.